News for Fortress Biotech, Inc. (FBIO)

Texas-based Volcon, Inc. (VLCN) is up over 161 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Payer coverage for Emrosiâ„¢ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as pre

Canada-based Above Food Ingredients Inc. (ABVE) is up over 115 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively

Emrosiâ„¢ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy indepen

**media[649436]**

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% roya

Below are press releases from companies with preferred stock and baby bonds outstanding. Additionally, news of a more macro economic importance may be posted. May 15, 2025 16:05 ET | Source: Fortress Biotech, Inc. Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights May 15, 2025 15:14 ET | Source: Hovnanian Enterprises, Inc. Hovnanian Enterprises Announces Strategic Partnership

Emrosiâ„¢ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired

Revenue: $13.1 million for the first quarter, surpassing the estimated $11.62 million.Earnings Per Share (EPS): Details not provided in the filing, but the est

Fortress Biotech (FBIO) reported Q1 2025 financial results with a consolidated cash increase to $91.3 million. Sun Pharma's pending acquisition of Check

UNLOXCYTâ„¢ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma

**media[618055]**

Fortress Biotech (FBIO) to participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025. The company's CEO, Lindsay

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[579425]**

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ETCompany ParticipantsJaclyn Jaffe - Senior Director, Corporate...

Fortress Biotech (FBIO) set to announce FY earnings March 26th. Discover EPS & revenue estimates, historical performance, and key insights.

Fortress Biotech Inc (FBIO) is set to release its Q4 2024 earnings on Mar 26, 2025. The consensus estimate for Q4 2024 revenue is $16.30 million, and the earnin